Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation

Dig Dis Sci. 1996 Jun;41(6):1054-6. doi: 10.1007/BF02088218.

Abstract

In patients with hepatorenal syndrome (HRS), 4-hr administration of a vasopressin analog has recently been shown to benefit renal blood flow and renal function. However, long-term effects and tolerance of this treatment have not been reported. We report a case of HRS that was controlled by the vasopressin analog, terlipressin. Because HRS repeatedly relapsed when treatment was discontinued, terlipressin, 2 mg/day was administered for 67 days, until liver transplantation could be performed in a patient with normal renal function. Except for limited cutaneous necrosis at an injection point, prolonged treatment with this vasopressin analog was well tolerated.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Female
  • Hepatorenal Syndrome / drug therapy*
  • Hepatorenal Syndrome / physiopathology
  • Hepatorenal Syndrome / surgery
  • Humans
  • Infusions, Intravenous
  • Liver Transplantation*
  • Lypressin / administration & dosage
  • Lypressin / analogs & derivatives*
  • Lypressin / therapeutic use
  • Terlipressin
  • Time Factors
  • Vasoconstrictor Agents / administration & dosage
  • Vasoconstrictor Agents / therapeutic use*

Substances

  • Vasoconstrictor Agents
  • Lypressin
  • Terlipressin